These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 15774500)

  • 21. Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor.
    Li Y; Suino K; Daugherty J; Xu HE
    Mol Cell; 2005 Aug; 19(3):367-80. PubMed ID: 16061183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of the retinoid orphan-related receptor-alpha coactivator binding interface: a structural basis for ligand-independent transcription.
    Harris JM; Lau P; Chen SL; Muscat GE
    Mol Endocrinol; 2002 May; 16(5):998-1012. PubMed ID: 11981035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor.
    Gee AC; Carlson KE; Martini PG; Katzenellenbogen BS; Katzenellenbogen JA
    Mol Endocrinol; 1999 Nov; 13(11):1912-23. PubMed ID: 10551784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural consequences of D481N/K483Q mutation at glycine binding site of NMDA ionotropic glutamate receptors: a molecular dynamics study.
    Blaise MC; Bhattacharyya D; Sowdhamini R; Pradhan N
    J Biomol Struct Dyn; 2005 Feb; 22(4):399-410. PubMed ID: 15588104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms.
    Hultman ML; Krasnoperova NV; Li S; Du S; Xia C; Dietz JD; Lala DS; Welsch DJ; Hu X
    Mol Endocrinol; 2005 Jun; 19(6):1460-73. PubMed ID: 15761029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Residues in the ligand binding domain that confer progestin or glucocorticoid specificity and modulate the receptor transactivation capacity.
    Robin-Jagerschmidt C; Wurtz JM; Guillot B; Gofflo D; Benhamou B; Vergezac A; Ossart C; Moras D; Philibert D
    Mol Endocrinol; 2000 Jul; 14(7):1028-37. PubMed ID: 10894152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of ligand binding on the association properties and conformation in solution of retinoic acid receptors RXR and RAR.
    Egea PF; Rochel N; Birck C; Vachette P; Timmins PA; Moras D
    J Mol Biol; 2001 Mar; 307(2):557-76. PubMed ID: 11254382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binding mode prediction for a flexible ligand in a flexible pocket using multi-conformation simulated annealing pseudo crystallographic refinement.
    Ota N; Agard DA
    J Mol Biol; 2001 Nov; 314(3):607-17. PubMed ID: 11846570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure/function of the human glucocorticoid receptor: tyrosine 735 is important for transactivation.
    Ray DW; Suen CS; Brass A; Soden J; White A
    Mol Endocrinol; 1999 Nov; 13(11):1855-63. PubMed ID: 10551779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conformational dynamics of the estrogen receptor alpha: molecular dynamics simulations of the influence of binding site structure on protein dynamics.
    Celik L; Lund JD; Schiøtt B
    Biochemistry; 2007 Feb; 46(7):1743-58. PubMed ID: 17249692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic communication between androgen and coactivator: mutually induced conformational perturbations in androgen receptor ligand-binding domain.
    Xu X; Yang W; Wang X; Li Y; Wang Y; Ai C
    Proteins; 2011 Apr; 79(4):1154-71. PubMed ID: 21322031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain.
    Biggadike K; Bledsoe RK; Hassell AM; Kirk BE; McLay IM; Shewchuk LM; Stewart EL
    J Med Chem; 2008 Jun; 51(12):3349-52. PubMed ID: 18522385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The conserved residue Phe273(282) of PPARalpha(gamma), beyond the ligand-binding site, functions in binding affinity through solvation effect.
    Yue L; Ye F; Xu X; Shen J; Chen K; Shen X; Jiang H
    Biochimie; 2005 Jun; 87(6):539-50. PubMed ID: 15935279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural insights into the molecular mechanism of vitamin D receptor activation by lithocholic acid involving a new mode of ligand recognition.
    Belorusova AY; Eberhardt J; Potier N; Stote RH; Dejaegere A; Rochel N
    J Med Chem; 2014 Jun; 57(11):4710-9. PubMed ID: 24818857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insights into ligand selectivity in estrogen receptor isoforms: molecular dynamics simulations and binding free energy calculations.
    Zeng J; Li W; Zhao Y; Liu G; Tang Y; Jiang H
    J Phys Chem B; 2008 Mar; 112(9):2719-26. PubMed ID: 18266357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular structure of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D3 hormone analogues and a LXXLL-containing coactivator peptide.
    Vanhooke JL; Benning MM; Bauer CB; Pike JW; DeLuca HF
    Biochemistry; 2004 Apr; 43(14):4101-10. PubMed ID: 15065852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular mechanism of allosteric communication in the human PPARalpha-RXRalpha heterodimer.
    Venäläinen T; Molnár F; Oostenbrink C; Carlberg C; Peräkylä M
    Proteins; 2010 Mar; 78(4):873-87. PubMed ID: 19847917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of action of Hic-5/androgen receptor activator 55, a LIM domain-containing nuclear receptor coactivator.
    Heitzer MD; DeFranco DB
    Mol Endocrinol; 2006 Jan; 20(1):56-64. PubMed ID: 16141357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unraveling the Allosteric Cross-Talk between the Coactivator Peptide and the Ligand-Binding Site in the Glucocorticoid Receptor.
    La Sala G; Gunnarsson A; Edman K; Tyrchan C; Hogner A; Frolov AI
    J Chem Inf Model; 2021 Jul; 61(7):3667-3680. PubMed ID: 34156843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ligand-escape pathways from the ligand-binding domain of PPARgamma receptor as probed by molecular dynamics simulations.
    Genest D; Garnier N; Arrault A; Marot C; Morin-Allory L; Genest M
    Eur Biophys J; 2008 Apr; 37(4):369-79. PubMed ID: 17929009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.